Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma

Oscar Calzada, Jeffrey M. Switchenko, Joseph J. Maly, Kristie A. Blum, Natalie Grover, Stephanie Mathews, Steven I. Park, Max Gordon, Alexey Danilov, Narendranath Epperla, Timothy S. Fenske, Mehdi Hamadani, Christopher R. Flowers, Jonathon B. Cohen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p = .001), have no B symptoms (83 versus 65% p = .003) and have normal LDH levels at diagnosis (87 versus 55% p < .001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p = .407).

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Apr 18 2018

Fingerprint

Mantle-Cell Lymphoma
Therapeutics
Cohort Studies
Safety

Keywords

  • deferred therapy
  • Mantle cell lymphoma
  • non-Hodgkin’s lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Calzada, O., Switchenko, J. M., Maly, J. J., Blum, K. A., Grover, N., Mathews, S., ... Cohen, J. B. (Accepted/In press). Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leukemia and Lymphoma, 1-9. https://doi.org/10.1080/10428194.2018.1455973

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. / Calzada, Oscar; Switchenko, Jeffrey M.; Maly, Joseph J.; Blum, Kristie A.; Grover, Natalie; Mathews, Stephanie; Park, Steven I.; Gordon, Max; Danilov, Alexey; Epperla, Narendranath; Fenske, Timothy S.; Hamadani, Mehdi; Flowers, Christopher R.; Cohen, Jonathon B.

In: Leukemia and Lymphoma, 18.04.2018, p. 1-9.

Research output: Contribution to journalArticle

Calzada, O, Switchenko, JM, Maly, JJ, Blum, KA, Grover, N, Mathews, S, Park, SI, Gordon, M, Danilov, A, Epperla, N, Fenske, TS, Hamadani, M, Flowers, CR & Cohen, JB 2018, 'Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma', Leukemia and Lymphoma, pp. 1-9. https://doi.org/10.1080/10428194.2018.1455973
Calzada, Oscar ; Switchenko, Jeffrey M. ; Maly, Joseph J. ; Blum, Kristie A. ; Grover, Natalie ; Mathews, Stephanie ; Park, Steven I. ; Gordon, Max ; Danilov, Alexey ; Epperla, Narendranath ; Fenske, Timothy S. ; Hamadani, Mehdi ; Flowers, Christopher R. ; Cohen, Jonathon B. / Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. In: Leukemia and Lymphoma. 2018 ; pp. 1-9.
@article{ca2d480734c74b92ae04afb52c655467,
title = "Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma",
abstract = "Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18{\%}) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44{\%} p = .001), have no B symptoms (83 versus 65{\%} p = .003) and have normal LDH levels at diagnosis (87 versus 55{\%} p < .001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95{\%} CI 0.22–1.84, p = .407).",
keywords = "deferred therapy, Mantle cell lymphoma, non-Hodgkin’s lymphoma",
author = "Oscar Calzada and Switchenko, {Jeffrey M.} and Maly, {Joseph J.} and Blum, {Kristie A.} and Natalie Grover and Stephanie Mathews and Park, {Steven I.} and Max Gordon and Alexey Danilov and Narendranath Epperla and Fenske, {Timothy S.} and Mehdi Hamadani and Flowers, {Christopher R.} and Cohen, {Jonathon B.}",
year = "2018",
month = "4",
day = "18",
doi = "10.1080/10428194.2018.1455973",
language = "English (US)",
pages = "1--9",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma

AU - Calzada, Oscar

AU - Switchenko, Jeffrey M.

AU - Maly, Joseph J.

AU - Blum, Kristie A.

AU - Grover, Natalie

AU - Mathews, Stephanie

AU - Park, Steven I.

AU - Gordon, Max

AU - Danilov, Alexey

AU - Epperla, Narendranath

AU - Fenske, Timothy S.

AU - Hamadani, Mehdi

AU - Flowers, Christopher R.

AU - Cohen, Jonathon B.

PY - 2018/4/18

Y1 - 2018/4/18

N2 - Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p = .001), have no B symptoms (83 versus 65% p = .003) and have normal LDH levels at diagnosis (87 versus 55% p < .001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p = .407).

AB - Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p = .001), have no B symptoms (83 versus 65% p = .003) and have normal LDH levels at diagnosis (87 versus 55% p < .001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p = .407).

KW - deferred therapy

KW - Mantle cell lymphoma

KW - non-Hodgkin’s lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85048791473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048791473&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1455973

DO - 10.1080/10428194.2018.1455973

M3 - Article

C2 - 29912594

AN - SCOPUS:85048791473

SP - 1

EP - 9

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -